Gary V. Walker

Gary V. Walker

Auto-generated profile, based on publicly available information

Gary V. Walker

Division of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
GWGary V. Walker
Gary V. Walker
FSFerial Shihadeh
Ferial Shihadeh
HKHagop Kantarjian
Hagop Kantarjian
PAPamela Allen
Pamela Allen
GRGabriela Rondon
Gabriela Rondon
Bouthaina S. DabajaBouthaina S. Dabaja
Bouthaina S. Dabaja

1 January 2022 in Brachytherapy
Verified
Journal Article
Closed access
LALauren Andring
Lauren Andring
AYAlison Yoder
Alison Yoder
TPTodd Pezzi
Todd Pezzi
CTChad Tang
Chad Tang
RKRachit Kumar
Rachit Kumar
GWGary V. Walker
Gary V. Walker

1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
GWGary V. Walker
Gary V. Walker
SGStephen R. Grant
Stephen R. Grant
RJReshma Jagsi
Reshma Jagsi
BSBenjamin D. Smith
Benjamin D. Smith

16 May 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ASAlexander Sherry
Alexander Sherry
CHCara Haymaker
Cara Haymaker
SWShuqi Wang
Shuqi Wang
SLSuyu Liu
Suyu Liu
TBTharakeswara K. Bathala
Tharakeswara K. Bathala
CTChad Tang
Chad Tang
PURPOSE: We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS: EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS: From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION: The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.

1 August 2018 in Journal of Oncology Practice
Verified
Journal Article
Closed access
GWGary V. Walker
Gary V. Walker
SSShervin M. Shirvani
Shervin M. Shirvani
YBYerko Borghero
Yerko Borghero
MCMatthew D. Callister
Matthew D. Callister
DCDaniel D. Chamberlain
Daniel D. Chamberlain
ALAnna O. Likhacheva
Anna O. Likhacheva
Purpose: Shorter fractionation radiation regimens for palliation of bone metastases result in lower financial and social costs for patients and their caregivers and have similar efficacy as longer fractionation schedules, although practice patterns in the United States show poor adoption. We investigated whether prospective peer review can increase use of shorter fractionation schedules. Methods: In June 2016, our practice mandated peer review of total dose and fractionation for all patients receiving palliative treatment during our weekly chart rounds. We used descriptive statistics and Fisher’s exact test to compare lengths of treatment of uncomplicated bone metastases before and after implementation of the peer review process. Results: Between July 2015 and December 2016, a total of 242 palliative treatment courses were delivered, including 105 courses before the peer review intervention and 137 after the intervention. We observed greater adoption of shorter fractionation regimens after the intervention. The use of 8 Gy in one fraction increased from 2.8% to 13.9% of cases postadoption. Likewise, the use of 20 Gy in five fractions increased from 25.7% to 32.8%. The use of 30 Gy in 10 fractions decreased from 55.2% to 47.4% ( P = .002), and the use of ≥ 11 fractions decreased from 16.2% before the intervention to 5.8% after ( P = .006). Conclusion: Prospective peer review of palliative regimens for bone metastases can lead to greater adoption of shorter palliative fractionation schedules in daily practice, in accordance with national guidelines. This simple intervention may therefore benefit patients and their caregivers as well as provide value to the health care system.

1 September 2018 in Practical Radiation Oncology
Verified
Journal Article
Closed access
SGStephen R. Grant
Stephen R. Grant
BSBenjamin D. Smith
Benjamin D. Smith
ALAnna O. Likhacheva
Anna O. Likhacheva
SSShervin M. Shirvani
Shervin M. Shirvani
DRDavid B. Rosen
David B. Rosen
GWGary V. Walker
Gary V. Walker